About Cerecor
Cerecor is a company based in Baltimore (United States) founded in 2011. Cerecor has raised $45.2 million across 6 funding rounds from investors including NIH, Hercules Capital and Maxim Group. The company has 20 employees as of December 31, 2022. Cerecor has completed 3 acquisitions, including Aevi Genomic Medicine, Karbinal ER and Trxpharma. Cerecor offers products and services including AVTX-009, Quisovalimab, and AVTX-008. Cerecor operates in a competitive market with competitors including Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Alto Neuroscience, among others.
- Headquarter Baltimore, United States
- Employees 20 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Avalo Therapeutics, Inc.
-
Annual Revenue
$18.05 M (USD)234as on Dec 31, 2022
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$45.2 M (USD)
in 6 rounds
-
Latest Funding Round
$5 M (USD), Post-IPO
Apr 28, 2017
-
Investors
NIH
& 6 more
-
Employee Count
20
as on Dec 31, 2022
-
Investments & Acquisitions
Aevi Genomic Medicine
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cerecor
Cerecor offers a comprehensive portfolio of products and services, including AVTX-009, Quisovalimab, and AVTX-008.
Targets inflammatory diseases via anti-IL-1β for immune dysregulation
Anti-LIGHT mAb for treating immune dysregulation disorders
BTLA agonist to modulate immune responses in therapies
People of Cerecor
Unlock access to complete
Unlock access to complete
Funding Insights of Cerecor
Cerecor has successfully raised a total of $45.2M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in April 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cerecor
Cerecor has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Hercules Capital and Maxim Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Apple Tree Partners is engaged in life sciences venture capital.
|
Locked | Locked | Locked |
Investor details for Cerecor
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cerecor
Cerecor has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Aevi Genomic Medicine, Karbinal ER and Trxpharma.
Investment portfolio details for Cerecor
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Information on allergy drugs is provided through an online platform.
|
Locked | Locked | 2011 | Locked | |
|
Therapeutics for rare diseases in neurology and hematology are developed.
|
Locked | Locked | 2001 | Locked | |
|
-
|
Locked | Locked | 0 | Locked |
Complete acquisition details for Cerecor
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Cerecor
Detailed financials for Cerecor
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cerecor Comparisons
Peer comparison for Cerecor
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cerecor
Cerecor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Alto Neuroscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
Detailed competitors of Cerecor
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cerecor
Complete news archive for Cerecor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cerecor
Cerecor was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Cerecor is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Cerecor is a funded company, having raised a total of $45.2M across 6 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Cerecor is 20.
Annual revenue of Cerecor is $18.05M as on Dec 31, 2022.
Founded in 2011, Cerecor operates from Baltimore, United States, within the biotechnology sector. Focus is placed on developing treatments for immunological and neurological conditions. The pipeline encompasses CERC-002, targeted at pediatric Crohns disease; CERC-007, aimed at inflammatory arthritis and multiple myeloma; and CERC-802 along with CERC-803, directed toward congenital disorders. Efforts center on advancing these therapeutic candidates through clinical stages.
Cerecor's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alto Neuroscience.
Cerecor offers AVTX-009, Quisovalimab, and AVTX-008.
Cerecor has made 3 acquisitions, including Aevi Genomic Medicine, Karbinal ER, and Trxpharma.
Cerecor has 7 investors. Key investors include NIH, Hercules Capital, Maxim Group, Armistice Capital, and Turmeric Acquisition Corp.